Compare EHang Holdings Ltd - ADR (EH) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? EHang Holdings Ltd - ADR trades at $3.74 (market cap $289.73M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 3.4× EHang Holdings Ltd - ADR's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 47 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EH | MRVI | |
|---|---|---|
Market Cap | $289.73M | $972.90M |
Volume | 749,255 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $18.94 | $9.00 |
52-Week Low | $3.78 | $2.83 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $241.33M | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $3.78, down 4.79% on the day, reflecting a bearish technical trend. The company reported revenue of $418 million for 2025 but posted a net loss of $276 million, with negative profit margins and ROE. Recent news includes a law firm investigation into investor claims and expansion of its Global Fast Track Program to Vietnam. Cash flow from operations turned positive in 2024 at $158 million, but investing activities remain heavily negative due to capital expenditures.
The outlook is highly speculative, with significant execution and regulatory risks. Investment opportunity hinges on successful commercialization of eVTOL technology, but persistent losses and bearish analyst sentiment suggest caution. Key risks include ongoing legal scrutiny, intense competition, and reliance on future regulatory approvals for growth.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
